Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323666 | 0.94 | KCNH2 (0.90) | RENKCNH2CYP3A4 | |
| SCHEMBL13323669 | 0.92 | KCNH2 (0.85) | RENKCNH2CYP3A4 | |
| SCHEMBL3124847 | 0.92 | KCNH2 (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL3122399 | 0.91 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL3034460 | 0.90 | REN (0.91) | RENKCNH2CYP3A4 | |
| SCHEMBL3132694 | 0.90 | REN (0.96) | RENKCNH2CYP3A4 | |
| SCHEMBL3040475 | 0.89 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL3251287 | 0.88 | REN (0.91) | RENKCNH2CYP3A4 | |
| SCHEMBL3124522 | 0.88 | REN (1.00) | RENKCNH2CYP3A4 | |
| SCHEMBL3122463 | 0.88 | REN (0.91) | RENKCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343968-B2 | Case of renin inhibitors | MERCK CANADA INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-8343968-B2 | Case of renin inhibitors | MERCK CANADA INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-8343968-B2 | Case of renin inhibitors | MERCK CANADA INC. (CA) | 2013-01-01 | — | — | US | disclosed |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-05-13 | — | — | US | disclosed |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-05-13 | — | — | US | disclosed |
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2010-05-13 | — | — | US | disclosed |
| WO-2008141462-A9 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2009-01-08 | — | — | WO | disclosed |
| WO-2008141462-A1 | NOVEL CASE OF RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120859-A1 | NOVEL CASE OF RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885KCNH2 1085/4885CYP3A4 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.